Phase IIb Study of Boehringer Ingelheim’s Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment

New data from a pre-specified interim analysis of the Phase IIb SOUND-C2 study show that 68 percent of genotype-1 (GT1) hepatitis C virus (HCV) patients achieved sustained viral response 12 weeks after the end of treatment with Boehringer Ingelheim’s investigational direct-acting antiviral compounds — the protease inhibitor BI 201335 and polymerase inhibitor BI 207127 — plus ribavirin, without interferon.
MarketWatch